Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF 301 trial Journal Article
| Authors: | Makawita, S.; Abou-Alfa, G. K.; Roychowdhury, S.; Sadeghi, S.; Borbath, I.; Goyal, L.; Cohn, A.; Lamarca, A.; Oh, D. Y.; MacArulla, T.; Shroff, R. T.; Howland, M.; Li, A.; Cho, T.; Pande, A.; Javle, M. |
| Article Title: | Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF 301 trial |
| Abstract: | Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic FGFR-altered cholangiocarcinomas has led to its further investigation in the front-line setting. In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to standard of care gemcitabine and cisplatin in advanced/metastatic cholangiocarcinoma with FGFR2 translocations. The results of this study have the potential to define a new role for a chemotherapy-free, targeted therapy option in the front-line setting for these patients. © 2020 Future Medicine Ltd. |
| Keywords: | targeted therapy; cholangiocarcinoma; fibroblast growth factor receptor inhibitor; infigratinib |
| Journal Title: | Future Oncology |
| Volume: | 16 |
| Issue: | 30 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2020-10-01 |
| Start Page: | 2375 |
| End Page: | 2384 |
| Language: | English |
| DOI: | 10.2217/fon-2020-0299 |
| PUBMED: | 32580579 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2020 -- Source: Scopus |
